Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
transplant
| Question | Answer |
|---|---|
| Basilixmab | Simulect |
| Basiliximab MOA | IL-2 receptor antagonist monoclonal antibodu that inhibits IL-2 receptor |
| Antithymocytes Globulin: Equine | Atgam |
| Antithymocytes Globulin: Rabbit | Thymoglobulin |
| Antithymocytes Globulin MOA | Bind to antigens on T-lymphocytes and interfere with their function |
| WHat phase of transplat is Basilixmab used for | induction immunosuppressant |
| What phase of transplant is Antithymycytes used in | Induction immunosuppressant |
| Cyclosporin: modified | Gengraf Neoral |
| Cyclosporin: non-modified | sandimmune |
| Cyclosporin Opthalmic for dry eyes | Restasis |
| Cyclosporin MOA | Calcineurin inhibitor: |
| Calcineurin inhibitor MOA | suppress cellular immunity by inhibiting T-lymphocyte activation |
| Cyclosporin goal trough level | 100-400 ng/mL |
| Cyclosporin Side effects | Increased BG, Hyperkalemia, hypomagnesium, hirsutism, gingival hyperplasia, neurotoxicity, hyperuricemia |
| Cyclosporin monitoring | Trough levels, serum electrolytes ( K and Mg) renal function, LFT, BP, BG, lipid profile |
| Cyclosporin has drug interactions with | CYP3A4 inhibitors |
| Cyclosporin oral formulation should never be administer in | plastic or styrofoam cup |
| tacrolimus | Prograg |
| Tacrolimus MOA | calcinuerin inhibitor |
| Tacrolimus ER tablet | Envarsus XR |
| Tacrolimus topical for eczema | Protopic |
| Tacrolimus goal trough | 3-15 mg/mL |
| Tacrolimus Boxed warning | increased risk of malignancy and infection |
| Tacrolimus side effets | increased BG and BP , hyperlipidema, nephrotoxicity, hypomagnesium, hypo/hyperkalemia, alopecia, neurotoxicity |
| Tacrolimus Monitor | trough lvels, serum K, mg, Phos, renal function, LFTs, BP, BG, lipid profile |
| Tacrolimus drug interactions | CYP 3A4 and Pgp |
| Tacrolimus and food | Tacrolimus should not be taken with food due to decrease absorption |
| Tacrolimus ER Capsule | Astagrag XL |
| Tacrolimus IV must be used with | non-PCV bag and lining |
| Azathioprine | Azasan |
| Azathioprine | Imuran |
| Azathioprine MOA | Anti-proliferative agents |
| Anti-proliferative agents MOA | inhibits T and B lymphocytes proliferation by altering purine nucleotide synthesis |
| Azathioprine Boxed warning | increased risk of malignancy ( lymphoma, skin cancer) |
| Azathipourine warnings | Myelosuppresion due to a genetic deficiency of thiopurine methyltransferase (TPMT) |
| Mycophenolate Mofetil | Cellcept |
| Mycophenolate Acid | Myfortic |
| Mycophenolate mofetil and Acid MOA | antiproliferative agnets |
| Cellcept and Myfortic Boxed warning | increased risk of congenital malformations and spontaneous abortions increaed risk of malignancy, skin cancer, and infections |
| Are cellcept and myfortic interchangable | NO |
| Cellcept and Mycfortic side effects | D/N/V abdominal pain , leukopenia |
| Cellcept 500mg = Myfortic | 360 mg Myfortic |
| Which mycophenolate is enteric coated | myfortic |
| Cellcept IV is only stable in | D5W |
| When should Cellcept IV not be given | polysorbate 80 |
| Mycophenolate can decrease the effectivness of what medication | oral contraceptives |
| Cellcept doing ` | 1-1.5 g PO/IV Q12 H |
| Myfortic | 360-720 mg PO Q12H |
| Everolimus | Zortress |
| Everolimus MOA | Mammalian target of rapamycin (mTOR) kinase inhibitor |
| Sirolimus | Rapamune |
| Sirolimus MOA | mammalian target of rapamycin (mTOR) Kinase inhibitor |
| mTOR kinase inhibitor | inhibits T-lymphocyte activation/proliferation may be synergenic with CNIs |
| Everolimus is not recommended in | heart transplant |
| Sirolimus is not recommended in | lung or liver transplant |
| mTOR kinase inhibitor warnings | Hyperlipidemia, impaired wound healing pneumonititis |
| Everolimus ( Zortress) should not be used within how many days of transplant | 30 days |
| mTOR kinase inhibitor | peripheral edema, increase BP or BG |
| Everolimus ( Zortress) tough goal level | 3-8 ng/mL |
| Sirolimus ( Rapamune) goal trough | 4-12 ng/mL |
| mTOR kinase inhibitors drug interactions | CYP3A4 inhibitors |
| Sirolimus Tablet and oral | are not bioequivalent |
| Belatacept MOA | inhibits T-lymphocyte activation and production of inflammatory mediators by binding to CD80 and CD86 on antigen presenting cell, blocking costimulation with CD28 on T-lymphocytes |
| Belatacept | Nulojix |
| Belatacept boxed warning | increased risk of post transplant lymphoproliferative disorfer (PTLD) increase risk of infection and malignancies |
| Belatacept boxed warning that it should only be used in | EBV seropositve patients in |
| Belatacept initial dosing | 10 mg/kg on days 1, 5, and then at the end of weeks 2, 4,8 and 12 after transplantation |
| Belatacept warning for | treat latent TB prior to use |
| Belatacept Maintence | 5 mg/kg at the end of week 16 |
| What body weight is used for belatacept dosing | TBW |
| Belatecept dosing should be rounded | to the nearest 12.5 mg |
| Pt should be screen for what prior to belatacept | TB and EBV ( Epstein Barr Virus) |
| what should be used with Belatacept | silicone free disposable syringe |
| Prednisone MOA | systemic steroid |
| Systemic steroid | naturally occuring hormones that prevent or suppress inflammatory and cytokine gene expression |
| short term side effects of systemic steroids | fluid retention, upset stomach, emotional instability, insomnia, increase appetite, weight gain, acute irse in blood glucose and BP |
| Long tern side effects of systemic steroids | adrenal suppresion/crushing syndrome, impaired wound healing, increase BP, diabetes, acene, osteoporosis, impaired growth in children |
| Azathioprine should be avoided with | Xanthine oxidase inhibitors ( allopurinol or febuxostat) |
| what are three monitoring questions for organ transplant team | is it a symptom of drug toxicity is it a symptom of organ rejection is it a symptom of an infection |
| what is a common symptom of acute rejection | flu like symptoms |
| symptoms of kidney transplant failure | decrease in urine output , fluid retention |
| which drugs for transplant require trough monitoring | calcinerrin inhibitors mTOR inhibitors |
| when shoul trough dosing be done | 30 mins before scheduled dose |
| symptoms of infection | Fever >100.4 f (38C) cough, more sputum or change in color of sputum , sore throat pain with passing urine, ear, or sinus pain, mouth sores, or a wound that does not heal |
| whar do acute rejections arise from | T-cell (cellular) or B-cell ( humoral or antibody) |
| how to distinguish between rejection types | biopsy |
| initial approach to treating acute cellular rejection | high dose steroids |
| Rituximab MOA | monoclonal antibody against CD20 antigen on B-cell |
| infection prophylaxis is essential when | the first 6 months post transplant and after receiving treatment for acute rejection |
| live vaccines can not be given post transplant which are life | M I C R O V Y |
| what cancer is common following transplant | skin cancer |
| tacrolimus frequency | q 12Hr or once daily in the morning for XL or XR formulations |
| Which transplant drug requires a MedGuide | Mycophenolate |
Created by:
annaiibarrera